Introduction Controversies remain regarding the safety of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this study, we seek to describe the infectious complications after tocilizumab in COVID patients and determine the related risk factors. Methods A single-center retrospective observational study was conducted among adult patients with SARS -CoV-2 infection admitted between 06/01/2020 and 12/31/2021 who received tocilizumab at our institution. Baseline demographics and laboratory values are obtained through reviewing electronic medical records. Risk factors of infectious complications after tocilizumab are identified through regression analysis. Statistics are performed using SPSS. P-value
Liu, Hongli; Niu, Chengu; Elkhapery, Ahmed; Zhu, Kaiwen; Nair, Lakshmi G; Anjum, Zauraiz; Iyer, Charoo; Faisal, Hafsa; and Chow, Ming
"Infectious complications after tocilizumab in patients with COVID: a real-world experience,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 13:
1, Article 3.
Available at: https://scholarlycommons.gbmc.org/jchimp/vol13/iss1/3